Beryl Drugs Faces Challenges Amid Shift to Mildly Bearish Trend in Evaluation

Beryl Drugs, a microcap company in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the technical landscape, moving from a bearish to a mildly bearish trend.
The stock's current price stands at 20.28, showing a notable change from the previous close of 19.32. Over the past year, Beryl Drugs has faced challenges, with a return of -29.83%, significantly underperforming the broader market, which recorded a return of -0.57%. The company's financial metrics indicate a weak long-term fundamental strength, highlighted by an average Return on Capital Employed (ROCE) of 7.27%.

Despite a modest annual growth rate in net sales of 12.86% and operating profit at 13.21% over the last five years, the company's ability to service its debt remains a concern, as evidenced by a low EBIT to Interest ratio of 0.86. Additionally, Beryl Drugs has experienced a decline in profits by 37% over the past year, further complicating its market position.

For those interested in the latest insights on Beryl Drugs, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.